FDA Updates Biliary Stent Clearance Guidance, Maintains Special 510(k) Exclusion
Executive Summary
The US FDA’s first revisions to its biliary stent guidance in more than two decades maintain substantial equivalence limitations that block the devices from the special 510(k) pathway. The restrictions are needed due to potential risks caused by off-label use of the stents in the vascular system, the agency says.